23rd Annual Meeting of the Japanese Society of Clinical Neuropsychopharmacology
jointly with 43rd Annual Meeting of Japanese Society of Newropsychopharmacology

October 24-26, 2013
OKINAWA CONVENTION CENTER, Okinawa, Japan

FIRST AUTHOR INDEX
First Name	Last Name	No.	Title
Berk	Michael	SL-1	Oxidative and immune biomarkers as targets for novel therapies
Phillips	Anthony G.	SL-2	Stress and cognition: A critical role for the prefrontal cortex
Zohar	Joseph	N-SL	DSM 5 and RDOC conceptual consideration and implication on diagnosis and treatment of Anxiety Disorders
Yatham	Lakshmi N.	CL-1	Promises of DSM.5 and the Current Realities: Implications for Bipolar Disorder Diagnosis and Treatment
REIJI	YOSHIMURA	C-S3-2	Predictions for responses to antidepressants: view from catecholamines, cytokines, and brain-derived neurotrophic factor
HIDENORI	YAMASUE	C/N-S5-2	Development of therapeutics for core symptoms of autism spectrum disorders: Clinical trials of intranasal oxytocin
TERUO	HAYASHI	N-S2-1	Molecular function of the endoplasmic reticular chaperone sigma-1 receptor
SHIZUKA	SHIMABUKURO	N-S4-4	ADHD: Where basic science meets clinical practice
TOMOYUKI	FURUYASHIKI	N-S8-4	Repeated stress-induced changes in dopaminergic functions in the medial prefrontal cortex in mice
SHIN	ONO	EN-2	The prevalence of glucose intolerance in Japanese schizophrenic patients with a normal fasting glucose level
YUTARO	SUZUKI	EN-3	Differences in plasma prolactin levels in patients with schizophrenia treated on monotherapy with five second-generation antipsychotics
MASAYA	YANAGI	AB-2	A potassium channel, Kv3.1, is reduced in schizophrenia and normalized with antipsychotic drugs; a possible new drug target for schizophrenia
Berk	Michael	LS2-D	Preventing depressive episodes in bipolar disorder: Maintenance therapy
Yatham	Lakshmi N.	LS2-E	Recent Advances in Diagnosis and Treatment of Bipolar Disorder
Zohar	Joseph	LS3-B	Science and nomenclature – Could infusion of neuroscience change an outdated psychotropic classification? An update
Phillips	Anthony G.	ES2-B	Prospects for more effective treatment of schizophrenia through innovations in neuropsychopharmacology
TAKASHI	WATANABE	O1-C5	5-HTTLPR genotype is the determinant of the therapeutic response and discontinuation of paroxetine initial treatment in panic disorder, not in major depressive disorder
KOICHI	NISHIJIMA	O1-D2	Temporal changes in serum creakine kinase concentration and degree of muscle rigidity in 24 patients with neuroleptic malignant syndrome
KAZUNARI	YOSHIDA	O1-D3	Abnormal involuntary movement and estimated dopamine D2 receptor occupancy in patients with schizophrenia: Analysis of the CATIE data
YUYA	MIZUNO	O1-D5	Polypharmacy to Counteract Antipsychotic-Induced Weight Gain and Metabolic Adverse Effects in Schizophrenia: A Systematic Review and Metaanalysis
TSUYOSHI	MIYAOKA	O3-C2	Efficacy and Safety of Yokukansan (TJ-54) in Treatment-Resistant Schizophrenia: A PANSS five-factor analysis
MUHAMMAD RASHEDUL	ISLAM	O3-D1	Rivastigmine improves the hippocampal neurogenesis and anti-depressivelike behaviors in olfactory bulbectomized mice
KENJI	HASHIMOTO	O3-D3	Role of BDNF-TrkB signaling in the inflammation-induced depression
SHIHO	KITAOKA	O3-D4	A role for neuron-microglia interaction through the innate immune signaling in emotional changes caused by repeated social defeat stress in mice
SHIGEKI	MORIGUCHI	O3-E5	Sigma-1 receptor stimulation improves depressive-like behaviors in CaMKIV null mice
MANABU	FUCHIKAMI	O3-E6	Pharmacological and optogenetic characterization of the critical PFC subregions underlying the rapid antidepressant actions of ketamine
KATSUTOSHI	YOKOYAMA	O3-C7	Milnacipran influences the indexes of I-metaiodobenzylguanidine (MIBG) scintigraphy in elderly depressed patients
YUKIE	KAWAHARA	O3-D12	Food reward-sensitive interaction of ghrelin and opioid receptor pathways in mesolimbic dopamine system
JUNZO	WATANABE	CNP1-10	The lipid profiles in Japanese patients with schizophrenia treated with antipsychotic agents
TARO	KISHI	CNP1-22	Efficacy and Tolerability of Perospirone in Schizophrenia: A Systematic Review and Meta-analysis of Randomized Controlled Trials
TARO	KISHI	CNP1-23	Augmentation of Antipsychotic Drug Action by Azapirone Serotonin1A Receptor Partial Agonists: A Meta-analysis
Yuki	Matsuda	CNP1-24	Updated Meta-analysis of NMDA Receptor Antagonists Interventions in Schizophrenia
TAKASHI	TSUBOI	CNP1-26	Predicting plasma concentration of olanzapine associated with dosage change: a population pharmacokinetic study
MASAKI	KATO	CNP1-34	Effect of brain volume-related SNPs of GSK3B gene on SSRI/SNRI treatment response in major depressive disorder
SHIGERU	MORINOBU	CNP1-35	Searching for epigenetic biomarkers in major depression: focusing on the serotonin signal transduction
WAKAKO	NAKANO	CNP1-61	Aripiprazole improves various cognitive and behavioral impairments after traumatic brain injury: a case report
MIZUKI	ASANO	CNP1-68	Effects of Ramelteon on Refractory Behavioral and Psychological Symptoms of Dementia in Alzheimer Disease
YUMIKO	AKAMINE	CNP1-77	Different effects of two transporting inhibitors, itraconazole and cimetidine on paliperidone enantiomers pharmacokinetics
RYOICHI	SADAHIRO	CNP1-78	Relationship between the C3435T MDR1 polymorphism and endogenous steroid hormones in healthy subjects
YUTARO	SUZUKI	CNP2-3	Changes in PR and QTc intervals after switching from olanzapine to risperidone in patients with stable schizophrenia
EIJI	HARADA	CNP2-34	Duloxetine: Effects of Dosing and Titration on Treatment Discontinuation in Patients with Major Depression
NORIAKI	SAGATA	NP2-43	A single-shot minocycline inhibits methamphetamine-induced behavioral sensitization in mice
EIICHI	TAIRA	NP2-51	Induction of endoplasmic reticulum stress related gene CHOP/Gadd153/ ddit3 in dopaminergic cells by methamphetamine
KAZUTAKA	OHI	NP2-61	Impacts of the genome-wide association mega-analysis supported variants on brain morphology in schizophrenia; a comprehensive VBM analysis
HIDENAGA	YAMAMORI	NP2-62	Plasma levels of mature brain-derived neurotrophic factor (BDNF) and matrix metalloproteinase-9 (MMP-9) in treatment-resistant schizophrenia treated with clozapine
MICHIKO	FUJIMOTO	NP2-66	Eye movement abnormalities in patients with schizophrenia
TATSUO	SHIBA	NP2-74	Involvement of autophagy signaling in Li2CO3-induced enhancement of the proliferation of neural stem/progenitor cells derived from the subventricular zone of adult mice
KOJI	OHIRA	NP2-82	Chronic fluoxetine treatment decreases parvalbumin and perineuronal nets in interneurons of frontal cortex and hippocampus of adult mice
AKIRA	NAKAJIMA	NP2-111	Nobiletin, a citrus flavonoid, improves cognitive impairment and reduces oxidative stress and tau hyperphosphorylation in SAMP8 mice
YUKI	KISHIKAWA	NP2-113	Effects of low-dose methylphenidate on attention-deficit hyperactivity disorder (ADHD)-like behaviors in the spontaneously hypertensive rat, an animal model of ADHD
RYOTA	SHINOHARA	NP2-116	A role for dopamine D1 receptor in the medial prefrontal cortex in regulating stress susceptibility in mice
SATOKO	HATTORI	NP2-117	In vivo evaluation of CNS in alpha-CaMKII heterozygous knockout mice using manganese-enhanced magnetic resonance imaging
SATOSHI	KUCHIIWA	NP2-121	A novel semi-automated method for measurement and quantitative analysis of aggressive biting behavior in male and female mice
TETSUYA	HASHIMOTO	NP2-141	Increased hippocampal quinone reductase 2 in Alzheimer’s disease
RIE	ISHIKAWA	NP2-144	Erasure of hippocampus-dependent fear memory by NMDA-glutamate receptor antagonist memantine
RYO	FUKUMORI	NP2-146	The role of uncoupling protein-2 in glutamate neurotoxicity with ischemia
YASUNORI	MATSUDA	NP2-155	Association of the clinical subtype and etiology for delirium with the outcome after risperidone monotherapy in patients having cancer